Biocept Stock Forecast, Price & News

Biocept (NASDAQ:BIOC) Frequently Asked Questions

Is Biocept a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biocept stock.
View analyst ratings for Biocept or view top-rated stocks.

How has Biocept's stock price been impacted by COVID-19 (Coronavirus)?

Biocept's stock was trading at $3.7690 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BIOC stock has increased by 4.8% and is now trading at $3.95.
View which stocks have been most impacted by COVID-19.

Are investors shorting Biocept?

Biocept saw a decrease in short interest in the month of October. As of October 29th, there was short interest totaling 461,900 shares, a decrease of 17.9% from the October 14th total of 562,900 shares. Based on an average daily trading volume, of 1,010,000 shares, the days-to-cover ratio is presently 0.5 days.
View Biocept's Short Interest.

When is Biocept's next earnings date?

Biocept is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for Biocept.

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) posted its quarterly earnings data on Monday, November, 15th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $0.06. The medical research company earned $17.47 million during the quarter, compared to the consensus estimate of $16.87 million. Biocept had a net margin of 4.71% and a trailing twelve-month return on equity of 10.35%. During the same quarter in the prior year, the firm posted ($0.43) EPS.
View Biocept's earnings history.

When did Biocept's stock split? How did Biocept's stock split work?

Biocept shares reverse split on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 4th 2020. An investor that had 100 shares of Biocept stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for BIOC?

3 equities research analysts have issued 12-month price targets for Biocept's stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate Biocept's stock price to reach $20.00 in the next year. This suggests a possible upside of 406.3% from the stock's current price.
View analysts' price targets for Biocept or view top-rated stocks among Wall Street analysts.

Who are Biocept's key executives?

Biocept's management team includes the following people:

• Michael W. Nall, President, Chief Executive Officer & Director
• Timothy C. Kennedy, CFO, Senior VP-Operations & Secretary
• Lyle J. Arnold, Chief Scientific Officer & Senior Vice President
• Michael C. Dugan, Chief Medical Officer & Medical Director
• Michael W. Brown, General Counsel, Compliance & Privacy Officer

What is Michael Nall's approval rating as Biocept's CEO?

1 employees have rated Biocept CEO Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among Biocept's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Biocept's key competitors?

Some companies that are related to Biocept include Celcuity (CELC), Enzo Biochem (ENZ), Exagen (XGN), Centogene (CNTG), OpGen (OPGN), Vyant Bio (VYNT), Psychemedics (PMD), CannLabs (CANL), PharmChem (PCHM), AnPac Bio-Medical Science (ANPC), American Shared Hospital Services (AMS), American Shared Hospital Services (AMS), CBA Florida (CBAI), First Choice Healthcare Solutions (FCHS) and Zicix (ZICX).
View all of BIOC's competitors.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Who are Biocept's major shareholders?

Biocept's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.89%), Marshall Wace LLP (0.71%), GSA Capital Partners LLP (0.63%), Renaissance Technologies LLC (0.35%), Jump Financial LLC (0.13%) and Goldman Sachs Group Inc. (0.13%).
View institutional ownership trends for Biocept.

Which institutional investors are selling Biocept stock?

BIOC stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, GSA Capital Partners LLP, and Geode Capital Management LLC.
View insider buying and selling activity for Biocept or view top insider-selling stocks.

Which institutional investors are buying Biocept stock?

BIOC stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Renaissance Technologies LLC, Jump Financial LLC, Goldman Sachs Group Inc., and Jane Street Group LLC.
View insider buying and selling activity for Biocept or or view top insider-buying stocks.

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $3.95.

How much money does Biocept make?

Biocept has a market capitalization of $66.53 million and generates $27.46 million in revenue each year. The medical research company earns $-17.81 million in net income (profit) each year or $0.22 on an earnings per share basis.

How many employees does Biocept have?

Biocept employs 107 workers across the globe.

What is Biocept's official website?

The official website for Biocept is www.biocept.com.

Where are Biocept's headquarters?

Biocept is headquartered at 5810 Nancy Ridge Drive, San Diego CA, 92121.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at (858) 320-8200, via email at [email protected], or via fax at 858-320-8225.